Status:
COMPLETED
Cannabis Effects on Brain Morphology in Aging
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Study Focuses on Brain Morphology and Cognition in Older Subjects
Eligibility:
All Genders
60-80 years
Brief Summary
Marijuana (Cannabis sativa) is the most widely used illicit drug worldwide, with 17.4 million Americans reporting past month use in 2010 and 4.6 million meeting criteria for dependence, underscoring t...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Subjects will be 60 heavy users or non-users between 60-80 years of age
- Participants who used marijuana during adolescence. Current marijuana usage not allowed and subjects must complete urine screening at the time of inclusion.
- Exclusion Criteria
- Major psychiatric disorders, such bipolar disorder or schizophrenia as revealed by the Structured Clinical Interview for DSM-IV Disorders (100) and exclude for confounding psychiatric conditions
- Evidence of untreated depression as determined by a HAM-D Score of \>12 (17-item version) or untreated anxiety by a score of \> 8 on the Hamilton Anxiety Scale
- Evidence of neurologic or other physical illness that could produce cognitive deterioration.
- Volunteers with a history of TIAs, carotid bruits, or lacunae on MRI scan will be excluded
- History of myocardial infarction within the previous year or unstable cardiac disease
- Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100)
- History of significant liver disease
- Clinically significant pulmonary disease, diabetes, or cancer
- Because medications can affect cognitive functioning, subjects needing medicines that could influence psychometric test results will be excluded. These include: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, systemic corticosteroids, benzodiazepines, medications with significant cholinergic or anticholinergic effects, anticonvulsants, or warfarin, and any affecting the serotonin system, which may affect neuropsychological test results.
- Current diagnosis or history of alcoholism or dependence on any illicit drugs other than marijuana.
- Use of any investigational drugs within the previous month or longer, depending on drug half-life.
- Contraindication for MRI scan (e.g. metal in body, claustrophobia).
Exclusion
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01874886
Start Date
January 1 2013
End Date
April 1 2019
Last Update
November 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Semel/Resnick Neuropsychiatric Institute
Los Angeles, California, United States, 90095